SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-24-034481
Filing Date
2024-08-02
Accepted
2024-08-02 17:22:46
Documents
13
Period of Report
2024-07-30
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 10-Q ovid-20240730.htm   iXBRL 8-K 27865
  Complete submission text file 0001628280-24-034481.txt   154537

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ovid-20240730.xsd EX-101.SCH 1898
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ovid-20240730_lab.xml EX-101.LAB 22548
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ovid-20240730_pre.xml EX-101.PRE 13044
15 EXTRACTED XBRL INSTANCE DOCUMENT ovid-20240730_htm.xml XML 2921
Mailing Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001
Business Address 441 NINTH AVENUE, 14TH FLOOR NEW YORK NY 10001 212-776-4381
Ovid Therapeutics Inc. (Filer) CIK: 0001636651 (see all company filings)

IRS No.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38085 | Film No.: 241172286
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)